Clinical Trial Update: Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) [Phase 3]

View source ↗

Summary

Phase 3 trial update for pembrolizumab with epacadostat or placebo in cisplatin-ineligible urothelial carcinoma; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Epacadostat (epacadostat)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Incyte Corporation | Conditions: UC (Urothelial Cancer) | Phase 3 | Status: COMPLETED | Results posted: 2019-08-29